Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abiomed (ABMD), Alnylam Pharma (ALNY) and Exelixis (EXEL).
Abiomed (ABMD)
Morgan Stanley analyst David Lewis maintained a Sell rating on Abiomed today and set a price target of $217.00. The company’s shares closed last Friday at $315.28, close to its 52-week high of $319.19.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 12.8% and a 68.7% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abiomed with a $298.40 average price target.
See today’s analyst top recommended stocks >>
Alnylam Pharma (ALNY)
In a report released today, David Lebovitz from Morgan Stanley maintained a Buy rating on Alnylam Pharma, with a price target of $197.00. The company’s shares closed last Friday at $146.57.
According to TipRanks.com, Lebovitz is a 2-star analyst with an average return of 0.7% and a 50.7% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Syndax Pharmaceuticals, and Ionis Pharmaceuticals.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $158.43, representing a 9.1% upside. In a report issued on July 29, Jefferies also maintained a Buy rating on the stock with a $179.00 price target.
Exelixis (EXEL)
Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Exelixis today and set a price target of $23.00. The company’s shares closed last Friday at $22.45.
According to TipRanks.com, Hung is a 4-star analyst with an average return of 13.6% and a 63.2% success rate. Hung covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Repare Therapeutics, and Acceleron Pharma.
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $31.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
